The following abstracts represent the presentations given at IWWM-7 Newport, Session-11:
Session Chair: Dr. Gertz (USA)
Should nucleoside analogues be used in young patients with WM? [YES] Dr. Morra (Italy)
Should nucleoside analogues be used in young patients with WM? [NO] Dr. Leleu (France)
Should Benda-R be considered for frontline therapy in WM? [YES] Dr. Rummel (Germany)
Should Benda-R be considered for frontline therapy in WM? [NO] Dr. Gregory (USA)
Should maintenance rituximab be used for rituximab responders in WM? [YES] Dr. Maloney (USA)
Should maintenance rituximab be used for rituximab responders in WM? [NO] Dr. Kimby (Sweden)
Should ASCT be a frontline option for WM? [YES] Dr. Barlogie (USA)
Should ASCT be a frontline option for WM? [NO] Dr. Fermand (France)